Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company.

Several equities analysts recently weighed in on BIOVF shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. HC Wainwright assumed coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company. Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Zacks Research raised shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th.

Swedish Orphan Biovitrum Price Performance

OTCMKTS:BIOVF opened at $48.16 on Monday. Swedish Orphan Biovitrum has a twelve month low of $29.18 and a twelve month high of $49.03. The firm has a market capitalization of $17.14 billion, a price-to-earnings ratio of 107.02 and a beta of 0.35. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average price is $48.34 and its two-hundred day moving average price is $44.29.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.